Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company founded in 2011, with a focus on advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of aggressive cancers. The company's slogan "Orchestrating the immune response to defeat cancer & infectious diseases" aptly summarizes its mission. Elicio leverages its expertise in immunology and immunotherapy to harness the natural power of the immune system, utilizing the innovative Amphiphile (“AMP”) technology. This technology enables the targeted delivery of therapeutic payloads directly to the lymph nodes, enhancing the immune system’s cancer-fighting capabilities. Through its research and development efforts, Elicio aims to optimize the lymph nodes’ natural ability to educate, activate, and amplify cancer-specific T cells, crucial for recognizing and eliminating tumor cells. The company's R&D pipeline includes off-the-shelf therapeutic cancer vaccines, namely ELI-002 targeting mKRAS-driven cancers, ELI-007 targeting BRAF-driven cancers, and ELI-008 targeting p53 hotspot mutations. Positioned at the core of the immune response, Elicio's AMP technology is designed to enhance the magnitude, potency, quality, and durability of the immune response to drive antitumor activity. Elicio Therapeutics received a significant $7.00M post-IPO equity investment from GKCC on 22 December 2023. The company operates in the biotechnology, healthcare, and pharmaceutical industries, with its headquarters in the United States. Overall, Elicio Therapeutics' innovative approach and promising pipeline position the company at the forefront of developing impactful immunotherapies for challenging cancers and infectious diseases. For more information, please visit www.elicio.com.